BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2016

May 25, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2016-05-23

Reporting Person: Stonehouse Jon P (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-05-23	Emp. Stock Option (Right to Buy)	$3.22	A	337050	Acquired	2026-05-23	Common Stock (337050)	Direct

Footnotes

F1: Retention Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.